Ranozex

Quick links to important sections

Ranozex

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ranozex

Quick Facts

Property Description
Active ingredient Ranolazine
Form Extended-release oral tablet
Pharmacological class Anti-anginal agent / Non-nitrate
Common use Management of chronic stable angina
Origin Synthetic (Piperazine derivative)

Ranozex: Definition and Pharmacological Classification

Ranozex is a prescription-only anti-anginal agent used for the long-term management of stable, chronic chest discomfort, known as angina pectoris. This medicine is part of a distinct cardiac therapeutic class and is clinically recognized for supporting heart function in patients whose symptoms are persistent.

The active ingredient is Ranolazine, which is a synthetic compound derived from piperazine. Ranolazine is a single-ingredient product and is differentiated by its classification as a non-nitrate. Pharmacological data supports Ranolazine's unique anti-ischemic profile. This finding supports the medication’s established role in easing angina symptoms by helping the heart muscle better manage its energy demands.

Composition, Origin, and Dosage Form

Ranozex is supplied for the oral route of administration in the form of an extended-release tablet. This specific oral dosage form is critical because it ensures the steady and sustained delivery of the active ingredient, Ranolazine, into the bloodstream over many hours.

The tablets are composed of Ranolazine and various pharmaceutical excipients needed to create the prolonged-release matrix. The extended-release formulation provides therapeutic benefit by maintaining stable drug concentrations, which is essential for consistent relief from recurrent angina. This characteristic helps ensure symptom management is predictable throughout the day and night.

General Purpose of Ranolazine

The general purpose of Ranolazine is to provide symptomatic relief to adults with stable angina pectoris whose condition is inadequately controlled by or who are intolerant to traditional anti-anginal therapies. The drug's primary benefit is achieved by enhancing the functional efficiency of the heart muscle.

This improved cardiac efficiency works to reduce the frequency of angina episodes and decrease their severity, thereby enhancing a patient’s overall capacity for daily activity. Ranolazine exerts its anti-ischemic effects by managing the electrical state of heart cells, allowing the heart muscle to relax more effectively—a typical neutral use scenario for Ranozex is to manage discomfort that persists even while the patient is on standard beta-blocker therapy.

Regulatory References

  1. Ranolazine - StatPearls - NCBI Bookshelf
  2. Ranexa EPAR Summary

What side effects are possible with Ranozex?

Possible Side Effects and Safety Information

The safety profile for Ranozex (ranolazine) is defined by official regulatory documents that classify potential adverse reactions based on their frequency of occurrence in clinical studies. Adverse events are grouped by the physiological system affected, providing a standardized overview of the medicine’s risk profile.

Frequency-Classified Adverse Reactions

Adverse reactions are reported under standard categories derived from regulatory frequency bands:

Classification Examples of Documented Reactions
Common Dizziness, Headache, Constipation, Nausea, Asthenia, Vomiting
Uncommon Syncope, Paresthesia, Hypotension, Dry mouth, Peripheral oedema
Rare Acute renal failure, Pancreatitis, Angioedema, Hyponatremia

Safety Constraints and Special Populations

Official labeling documents specific limitations and safety notes regarding the use of Ranozex. A key safety characteristic is its established potential to cause QTc interval prolongation, which is a documented change in the heart's electrical activity.

The medication is contraindicated in patients with pre-existing severe hepatic impairment, such as liver cirrhosis, and in those taking strong inhibitors of the CYP3A enzyme system. Furthermore, the safety profile notes that an increased incidence of adverse events has been observed in patients who are elderly and those with low body weight (le 60 kg).

While elevation of serum creatinine can occur, this effect is typically noted to be reversible upon discontinuation and does not show evidence of progression during long-term therapy.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

The information in this section is derived exclusively from official government regulatory sources regarding documented ranolazine overdose manifestations and mandated emergency actions.

Documented Overdose Manifestations

Official labeling indicates that ranolazine overdose is associated with symptoms primarily affecting the central nervous system (CNS) and gastrointestinal system, including nausea, vomiting, dizziness, confusion, tremor, double vision (diplopia), and numbness or tingling (paresthesia/hypoesthesia).

Serious concerns documented in the regulatory profile relate to the heart, with potential for QT interval prolongation (an ECG finding), low blood pressure (hypotension), and arrhythmias.

Regulatory Mandate for Emergency Action

In the event of a suspected overdose, it is officially required to seek emergency medical attention immediately. Individuals must call emergency services if the affected person has collapsed, has a seizure, is experiencing trouble breathing, or cannot be awakened.

No specific antidote is known for ranolazine overdose. Treatment is restricted to symptomatic and supportive care, which may include procedures like gastric lavage and the administration of activated charcoal if performed soon after ingestion. Continuous electrocardiographic (ECG) monitoring is required during management due to the documented risk of cardiac conduction changes.

Therapeutic Uses of Ranozex

The primary therapeutic role of Ranozex (ranolazine) is in the long-term symptomatic management of chronic stable angina pectoris. The medication is commonly used alone or with other therapies to help address the ongoing chest pain or pressure felt when the heart does not get enough oxygen. Ranozex is applied in situations where additional symptomatic support is needed.


This medication is relevant for conditions characterized by periods of heightened symptoms, such as chronic angina that remains persistent or is relevant when additional management of discomfort is required. It is primarily considered for managing symptoms that interfere with daily functioning, with the goal of easing the frequency of angina attacks and their overall severity. In practice, Ranozex may be part of symptomatic management to help patients cope more steadily with symptom fluctuations and supports the patient during episodes of heightened discomfort.

Ranozex may be part of symptomatic management to help with difficult episodes and assist with maintaining functional stability.

Quick Fact: Support for Chronic Chest Discomfort Property Description
Primary Use Management of chronic stable angina pectoris
Symptom Goal Easing the frequency and severity of anginal episodes
Clinical Context Applied in scenarios where additional management of discomfort is required
Patient Benefit Supports maintaining functional stability and comfort

Regulatory References

  1. NIH MedlinePlus overview of Ranolazine

Eligibility and Restrictions for Use

Who Can and Cannot Use Ranozex?

The official regulatory labeling for Ranozex (ranolazine) establishes specific population eligibility rules, defining who is allowed to use the medicine and who is absolutely prohibited from use.

Contraindicated Populations (Must Not Use)

Ranozex is contraindicated in patients with certain pre-existing conditions or when taking specific medications. Use is strictly prohibited in individuals with moderate or severe hepatic impairment (liver cirrhosis) and those with severe renal impairment (creatinine clearance less than 30 mL/ min). Additionally, Ranozex must not be taken with medications classified as strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin) or CYP3A inducers (e.g., rifampin, St. John's wort).

Age and Conditional Restrictions

Category Regulatory Status Restriction Context
Pediatric Use Safety and efficacy not established Use is not recommended in children under 18 years of age due to lack of data.
Pregnancy/Lactation Not recommended Regulatory agencies advise against use during pregnancy and while breastfeeding.
Conditional Use Caution is required Patients with mild hepatic impairment, mild to moderate renal impairment, low body weight (le 60 kg), or a known history of QT interval prolongation require careful monitoring.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Official regulatory information identifies specific drug classes and substances that interact with Ranozex (ranolazine), primarily through effects on drug metabolism and transport systems, which can significantly alter ranolazine or co-administered drug exposure. This information establishes the formal constraints for combination use.

Contraindicated Combinations

The co-administration of Ranozex is formally contraindicated by regulatory bodies with the following products due to the risk of either critically increased ranolazine levels or loss of therapeutic effect:

Substance Category Examples (Regulatory List)
Strong CYP3A Inhibitors Ketoconazole, Itraconazole, HIV Protease Inhibitors
CYP3A Inducers Rifampin, Phenytoin, St. John's wort
Antiarrhythmics Certain Class I A and Class III agents

Other Significant Interactions

Ranozex is officially documented as a mild inhibitor of CYP3A4, CYP2D6, P-glycoprotein (P-gp), and OCT2. This activity requires dose adjustment or caution when Ranozex is co-administered with:

  • Moderate CYP3A Inhibitors (e.g., Diltiazem, Verapamil): Ranozex exposure increases, necessitating regulatory limitations on the Ranozex dose.
  • Substrates of P-gp and OCT2 (e.g., Digoxin, Metformin): The exposure of these co-administered medicines increases, requiring specific dose constraints for the interacting drug.
  • QTc-Prolonging Drugs: Caution is advised due to the potential for an additive pharmacodynamic effect on the heart's electrical rhythm.

Furthermore, consumption of grapefruit or grapefruit juice is prohibited, as it acts as a strong CYP3A inhibitor and significantly increases ranolazine levels. Interaction risks are also heightened in patients with moderate to severe hepatic or severe renal impairment, leading to explicit contraindications for use in these populations.

Mechanism of Action

How Ranozex Works: Mechanism of Action

Ranozex (Ranolazine) functions primarily through selective inhibition of the late inward sodium current (mathbfINa,late) in cardiac myocytes. This persistent current is pathologically sustained under conditions of cellular stress. By blocking this excess Na^+ influx, Ranolazine initiates a mechanistic cascade that modulates the cardiac myocyte's internal ion composition.

This inhibition indirectly leads to a significant reduction in intracellular calcium ( Ca^2+) overload. Less Na^+ accumulation means the Na^+/ Ca^2+ Exchanger (NCX) supports Ca^2+ efflux. This resulting physiological effect prevents excessive Ca^2+ binding to contractile proteins, which decreases diastolic wall tension and promotes ventricular relaxation.

Auxiliarily, Ranolazine affects the cardiac energy substrate utilization pathway. This mechanism promotes a shift toward the more oxygen-efficient oxidation of glucose over fatty acids, modulating the myocardial oxygen supply-to-demand ratio under periods of oxygen constraint. This core mechanism is independent of significantly altering baseline heart rate or systemic blood pressure.

Dosage and Administration Information

How Ranozex is Used: Administration Guidelines

Administration Route and Form

Ranozex (ranolazine) is intended for oral administration only. It is supplied as an extended-release tablet, a specific dosage form designed to deliver the active ingredient over a sustained period.

To ensure proper, consistent release of the medication, the tablets must always be swallowed whole. They must not be crushed, broken, or chewed. Ranozex may be taken either with or without food.


Dosing Schedule and Titration

Ranozex is taken twice daily for the long-term management of chronic stable angina. Dosing typically begins with a low starting dose and is adjusted based on clinical response, a process known as titration.

Parameter 500 mg Base Regimen 375 mg Base Regimen
Initial Dose 500 mg twice daily 375 mg twice daily
Maximum Dose 1000 mg twice daily 750 mg twice daily

The dose is usually increased after 2–4 weeks if symptoms are not adequately managed. If a dose is missed, patients should skip the missed dose and take the next dose at the scheduled time; they should not take a double dose to compensate.


Usage in Specific Populations

Guidelines include specific rules for certain patient groups:

  • Older Adults: Caution is advised during dose titration in elderly patients.
  • Hepatic/Renal Impairment: Careful dose titration is recommended for patients with mild to moderate renal or mild hepatic impairment.
  • Pediatric Use: The safety and efficacy of Ranozex have not been established in children under 18 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ranozex


Evidence for Use in Chronic Stable Angina Pectoris

Ranozex was studied for the symptomatic management of chronic stable angina, a condition characterized by fluctuating or episodic manifestations of chest discomfort. The primary evidence for symptomatic changes was derived from short-term, randomized controlled trials (RCTs) that typically lasted only a few months. These studies were applied in research exploring short-term symptom changes in adults who were already taking standard anti-anginal drugs.

Researchers focused on outcomes related to physical discomfort and daily functioning. The findings describe measurements in which the Ranozex groups showed numerically greater changes in exercise duration and reductions in angina episode frequency compared to the placebo groups. However, because the follow-up durations were limited, the findings are relevant in trials assessing short-term or episodic symptom patterns.

Evidence in Patients with Coexisting Type 2 Diabetes

A separate, large-scale randomized trial was evaluated in a specific subpopulation of adults managing both chronic stable angina and Type 2 Diabetes Mellitus. The dedicated study reported that the measurements for angina episode frequency differed between the Ranozex group and the placebo group. This research focused on measuring short-term symptom changes.

Long-Term Follow-up and Cardiovascular Event Data

Most of the core studies supporting the medicine's use for stable angina were short-term. While some patients were observed in long-term extension studies, this research primarily tracked patterns related to safety rather than measuring the durability of symptomatic outcomes over many years. The efficacy studies for chronic stable angina were not designed to determine whether Ranozex may influence major clinical events like a heart attack or cardiovascular death. Therefore, limited information is available for long-term outcomes related to these serious endpoints in patients with stable angina.

What is Still Uncertain About the Ranozex Evidence Base

A key limitation is the lack of long-term evidence for the medicine's effect on major cardiovascular events in the approved population. Data for certain groups remain insufficient, and some exploratory studies examining the medicine for specific types of non-obstructive coronary disease were observed in some studies to have findings were mixed regarding physiological markers.

Frequently Asked Questions (FAQ)

Common questions about Ranozex (FAQ)


Q: How quickly should I expect to feel the effects of Ranozex after starting it?

A: Official information indicates that the dose of Ranozex is typically increased (titrated) after a few weeks if symptoms are not yet adequately managed. This indicates that the intended symptomatic effect is assessed and refined over a period of weeks during the dosage adjustment (titration) process.

Q: Will Ranozex help with all types of chest pain?

A: Ranolazine is specifically indicated only for the treatment of chronic stable angina pectoris. It is not approved for use in the acute treatment of an ongoing angina episode or for chest pain caused by other conditions.

Q: Why did my doctor prescribe Ranozex instead of a different chest pain medication?

A: Ranolazine is often prescribed as an add-on therapy. Official guidelines indicate it is approved for patients whose chronic stable angina is not adequately controlled by or who are unable to tolerate other first-line anti-anginal medicines, such as beta-blockers or calcium channel blockers.

Q: Does Ranozex have a 'loading dose' or do you start at the regular amount?

A: Ranolazine dosing does not involve a typical 'loading dose.' The recommended approach is to begin with a low initial dose. The dosage is then gradually adjusted (titrated) over time, based on how the patient responds to the medicine.

Q: Can Ranozex affect my sleep patterns?

A: Yes, it is possible. Regulatory documents list changes in sleep patterns as potential side effects. Specifically, both insomnia (difficulty sleeping) and somnolence (drowsiness or excessive sleepiness) are noted as uncommon adverse reactions.

Q: Is it normal to feel a little tired when first starting Ranozex?

A: Regulatory safety information lists asthenia as a common side effect. Asthenia is a medical term for a general lack of energy or physical weakness, which some patients may describe as feeling tired. Most common adverse events that lead to stopping the medication tend to occur early in the course of treatment.

Q: How long do I usually need to take Ranozex for chronic stable angina?

A: Official guidelines classify Ranozex as a long-term treatment. It is intended for the extended management of chronic stable angina, meaning its use typically continues over a prolonged duration unless a healthcare provider determines a change is necessary.

Q: What are the most serious, but rare, side effects associated with Ranozex?

A: Official safety documents classify a range of rare side effects. These include serious conditions such as pancreatitis and acute renal failure. These potential risks should be reviewed using the complete safety information or discussed with a healthcare professional.

Q: Does Ranozex work by opening up blood vessels?

A: Ranolazine's primary anti-anginal effect is not through opening up blood vessels (vasodilation). The main mechanism involves selectively inhibiting a specific electrical current in the heart muscle, which helps the heart relax and improves its energy efficiency.

Q: Do people typically gain or lose weight when taking Ranozex?

A: While not a common effect, official documents have noted 'weight decreased' as an uncommon side effect in clinical trials. Unusual changes in body weight have been reported overall, but the drug is not generally associated with significant weight changes.

Q: Are there any specific foods or drinks I should avoid while on Ranozex?

A: Yes, regulatory agencies advise that the consumption of grapefruit or grapefruit juice should be avoided. Grapefruit can significantly increase the concentration of ranolazine in the bloodstream.

Q: Why is Ranozex sometimes prescribed along with other heart medicines?

A: Ranozex is specifically approved as an add-on treatment for stable angina. This means it is used to provide symptomatic relief to patients who are still experiencing chest pain despite already taking standard anti-anginal drugs like beta-blockers or calcium antagonists.

Q: Does Ranozex interact with commonly prescribed cholesterol-lowering drugs (statins)?

A: Yes, Ranolazine can interact with certain statin medications, such as simvastatin and lovastatin. This interaction can increase the statin concentration in the body, which may require a limit on the maximum dose of the cholesterol-lowering drug.

Q: Does Ranozex interact with common anti-depressant medications?

A: Ranolazine may interact with certain types of anti-depressants. The drug inhibits the CYP2D6 enzyme, which is responsible for processing many common medications, including some tricyclic antidepressants. This interaction may lead to a need for dose adjustments for the co-administered anti-depressant.

Q: Is Ranozex used to prevent heart attacks?

A: No. According to the official evidence overview, the core studies supporting the medicine’s use were focused on relieving symptoms of chronic stable angina. They were not designed to determine whether Ranolazine prevents or influences major clinical events like a heart attack or cardiovascular death.

Q: Does Ranozex have any effect on blood sugar levels?

A: While the drug is not approved to treat diabetes, one large-scale study specifically evaluated Ranolazine in patients with coexisting stable angina and Type 2 Diabetes Mellitus. Some research suggests it may improve certain blood sugar markers, but this is an auxiliary observation.

Q: How long does Ranozex stay in your system after you stop taking it?

A: Based on official pharmacokinetics data, the drug is metabolized relatively quickly. The time it takes for the concentration to halve (the terminal half-life) is approximately 7 hours.

Q: Why do some people need a higher dose of Ranozex than others?

A: The dose is not fixed and is adjusted, or titrated, to the amount that best manages an individual patient's symptoms. This is done based on the clinical response. Other factors like low body weight or being an older adult may also necessitate a more cautious approach to dose adjustment.

Q: Can I take Ranozex if I have a history of heart rhythm problems?

A: The most important consideration is the potential for QT interval prolongation, a documented change in the heart's electrical activity. Caution is advised for patients with a known history of this condition or a family history of congenital long QT syndrome. Its use is generally acceptable for many other heart conditions.

Q: What are the symptoms of an overdose of Ranozex?

A: Symptoms of an accidental overdose may include general effects like dizziness, nausea, and vomiting. In the event of a significant overdose, the risk of exacerbating QTc prolongation (an electrical change in the heart) is heightened.

Q: What happens if I accidentally miss a dose of Ranozex?

A: Official administration guidelines advise that if a dose is missed, the patient should skip the missed dose entirely. The next dose should then be taken at the regularly scheduled time. It is not recommended to take a double dose to compensate for the one that was missed.

Q: Can Ranozex interact with medications for high blood pressure?

A: Ranolazine is known to affect the metabolism of certain drugs, including some that help manage blood pressure. Due to its potential to affect the heart’s electrical activity, caution is also advised when combining it with any other medications that have the potential to affect the QTc interval.

Q: Does Ranozex interact with common over-the-counter pain relievers like ibuprofen?

A: Official interaction lists focus on prescription drugs and known enzyme inhibitors. There is no specific caution in the regulatory documents against common non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, but it is important to review all co-administered drugs with a healthcare provider.

Q: Can older adults safely take Ranozex, and is the dosage different?

A: Use in older adults requires consideration. Official information advises caution during the dose adjustment (titration) process in elderly patients. Furthermore, an increased incidence of adverse events has been observed in older patients.

Q: What happens if I stop taking Ranozex suddenly?

A: While the prescribing information addresses a single missed dose, it does not explicitly detail the consequences of sudden discontinuation. Because Ranozex is used for long-term symptom management, abrupt cessation may lead to the return or worsening of angina symptoms.

How should Ranozex be stored and disposed of?

Official Storage and Disposal Requirements

Storage Condition Type: Controlled Room Temperature / Protection from Moisture
Labeled Temperature: Store between 59 F and 86 F (15 C to 30 C) [FDA].
Protection: Keep away from excess heat and moisture; do not freeze.
Container Rule: Must be kept in the original container, tightly closed.
Child Safety: Keep this and all medicines out of the sight and reach of children.
Disposal Instructions: Safely dispose of unused or expired medicine. The recommended method is a drug take-back program. If a program is unavailable, Ranozex can be mixed with an undesirable substance (e.g., coffee grounds) and sealed in a container for disposal in the household trash, as it is not on the FDA's flush list.

Official regulatory documents define the storage profile for Ranozex by mandating specific temperature constraints and requiring the tablets to be protected from environmental factors like moisture and heat. The profile strictly requires the product be kept in its original, tightly closed container and out of the reach of children to ensure safety. Disposal instructions prioritize drug take-back options and outline a secure, non-flushing method for discarding the unused product in the household trash when collection programs are unavailable.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ranozex found in:

A-Z Index: